LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Chiusa

SettoreSettore sanitario

127.83 -0.02

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

127.51

Massimo

128.01

Metriche Chiave

By Trading Economics

Entrata

50M

496K

Vendite

3M

149M

EPS

-0.294

Margine di Profitto

0.332

Dipendenti

682

EBITDA

-14M

-41M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.35% upside

Dividendi

By Dow Jones

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.5B

8.3B

Apertura precedente

127.85

Chiusura precedente

127.83

Notizie sul Sentiment di mercato

By Acuity

32%

68%

87 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Blueprint Medicines Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2025, 09:17 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 giu 2025, 05:31 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2 giu 2025, 13:50 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 giu 2025, 10:50 UTC

Acquisizioni, Fusioni, Takeovers

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 giu 2025, 10:05 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 giu 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 giu 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 giu 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 giu 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 giu 2025, 05:04 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 giu 2025, 05:04 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 giu 2025, 05:03 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Blueprint Medicines Corporation

2 giu 2025, 05:02 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Acquire Blueprint Medicines Corporation

Confronto tra pari

Modifica del prezzo

Blueprint Medicines Corp Previsione

Obiettivo di Prezzo

By TipRanks

1.35% in crescita

Previsioni per 12 mesi

Media 129.63 USD  1.35%

Alto 143 USD

Basso 105 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Blueprint Medicines Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

20 ratings

4

Acquista

16

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

87.66 / 99.25Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

87 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.